Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pancreatic Ductal AdenocarcinomaLiver, Cancer of, Primary Resectable
Interventions
DRUG

Ropivacaine 0.5%

Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.

DRUG

Normal Saline

Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER

NCT06214533 - Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery | Biotech Hunter | Biotech Hunter